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Efficacy and safety of oral ritlecitinib for
the treatment of active nonsegmental
vitiligo: A randomized phase 2b
clinical trial
Khaled Ezzedine, MD, PhD,a Elena Peeva, MD,b Yuji Yamaguchi, MD, PhD,c Lori Ann Cox, DO,d
Anindita Banerjee, PhD,e George Han, MD, PhD,f Iltefat Hamzavi, MD,g Anand K. Ganesan, MD, PhD,h
Mauro Picardo, MD, PhD,i Diamant Thaçi, MD, PhD,j John E. Harris, MD, PhD,k Jung Min Bae, MD, PhD,l
Katsuhiko Tsukamoto, MD, PhD,m Rodney Sinclair, MD,n Amit G. Pandya, MD,o,p Abigail Sloan, PhD,e
Dahong Yu, MD, PhD,b Kavita Gandhi, BS Pharm, MS,q Michael S. Vincent, MD, PhD,b and
Brett King, MD, PhDr

Background: Vitiligo is a chronic autoimmune disorder characterized by depigmented patches of the skin.
Objective: To evaluate the efficacy and safety of ritlecitinib, an oral JAK3 (Janus kinase)/TEC (tyrosine
kinase expressed in hepatocelluar carcinoma) inhibitor, in patients with active nonsegmental vitiligo in a
phase 2b trial (NCT03715829).
Methods: Patients were randomized to once-daily oral ritlecitinib 6 4-week loading dose (200/50 mg, 100/
50 mg, 30 mg, or 10 mg) or placebo for 24 weeks (dose-ranging period). Patients subsequently received
ritlecitinib 200/50 mg daily in a 24-week extension period. The primary efficacy endpoint was percent
change from baseline in Facial-Vitiligo Area Scoring Index at week 24.
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Results: A total of 364 patients were treated in the dose-ranging period. Significant differences from
placebo in percent change from baseline in Facial-Vitiligo Area Scoring Index were observed for the
ritlecitinib 50 mg groups with ( 21.2 vs 2.1; P \ .001) or without ( 18.5 vs 2.1; P \ .001) a loading dose
and ritlecitinib 30 mg group ( 14.6 vs 2.1; P = .01). Accelerated improvement was observed after treatment
with ritlecitinib 200/50 mg in the extension period (n = 187). No dose-dependent trends in treatmentemergent or serious adverse events were observed across the 48-week treatment.
Limitations: Patients with stable vitiligo only were excluded.
Conclusions: Oral ritlecitinib was effective and well tolerated over 48 weeks in patients with active
nonsegmental vitiligo. ( J Am Acad Dermatol https://doi.org/10.1016/j.jaad.2022.11.005.)
Key words: JAK inhibitor; JAK/STAT signaling; randomized clinical trial; ritlecitinib; skin depigmentation;
TEC inhibitor; VASI; vitiligo.

INTRODUCTION

JAK inhibitors represent a
CAPSULE SUMMARY
novel class of targeted immuVitiligo, an autoimmune
notherapy with demonstrated
depigmenting disorder has
efficacy in immune-mediated
a worldwide prevalence of
JAK3/TEC inhibition may decrease
diseases, including dermato0.5%-2.0% and impacts qualabnormal cytokine and T-cell signaling
logic
conditions.12,19-24
ity of life.1-4 Nonsegmental
involved in vitiligo pathogenesis, leading
vitiligo (NSV), characterized
Ritlecitinib is an orally
to repigmentation.
by symmetric body distribubioavailable small molecule
Treatment with ritlecitinib, an oral JAK3/
tion, accounts for 85%-90%
that inhibits JAK3 and the
TEC inhibitor, was well tolerated and
of cases.1,5-7 Vitiligo has
TEC
kinase
family.25
efficacious over 48 weeks in patients
an unpredictable clinical
Ritlecitinib is highly selective
8
with active nonsegmental vitiligo,
course. Spontaneous repigfor JAK3 over JAK1/JAK2/
supporting further investigation of
TYK2 and potently inhibits
mentation may occur in
ritlecitinib in phase 3 studies.
signaling of IL-2 and IL-15,
approximately 10% of vitiand thus, may be beneficial
ligo patients.9
for the treatment of vitiTreatment goals for vitiligo.15,25 Additionally, ritlecitinib may modulate
ligo include arresting progression, repigmentation of
existing lesions, and maintenance of repigmentaCD81 T cell cytotoxic activity by inhibiting the TEC
tion.10 Treatment options for vitiligo are limited and
family kinase inducible tyrosine kinase.25 Ritlecitinib
often require lengthy treatment and/or have limited
is under investigation for treatment of rheumatoid
efficacy.11-13 Current strategies for repigmentation
arthritis, alopecia areata, ulcerative colitis, and
Crohn’s disease.26-28 We evaluated the efficacy and
include narrow-band ultraviolet B phototherapy,
topical and systemic immunosuppressants, and sursafety of oral ritlecitinib in patients with active NSV in
gical procedures.1,11-13
a phase 2b study.
The current theory on vitiligo pathogenesis involves cytotoxic CD81 T cells that target melanoMETHODS
cytes and the cytokines IFN-g (interferon gamma),
Study design
IL-2 (interleukin 2), and IL-15.6,12,14,15 Notably, IL-2
This phase 2b, randomized, double-blind,
and IL-15 may activate and promote CD49a1/CD81
placebo-controlled, parallel-group, multicenter, and
tissue-resident memory T cells to induce melanocyte
dose-ranging study (NCT03715829) was conducted
apoptosis and maintain disease activity.14-16 IFN-g,
at 80 sites in Australia, Belgium, Canada, Germany,
IL-2, and IL-15 signal through the JAK (Janus kinase)/
Italy, Japan, South Korea, Spain, Taiwan, and the
STAT (signal transducer and activator of transcripUnited States from November 2018 to February 2021.
tion) pathway.17 The involvement of the T-cell
A 24-week dose-ranging period was followed by a
receptor in recognition of autoantigens suggests a
24-week extension period and 8-week follow-up.
contribution of tyrosine kinases expressed in the
The final protocol, any amendments, and informed
hepatocellular carcinoma (TEC) kinase family, such
consent documentation were approved by the instias inducible tyrosine kinase, which has been evoked
tutional review board/independent ethics committee
in T-cell-mediated autoimmune disorders.18
at each study center. This study was conducted in
d
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Abbreviations used:
AE:
BSA:
CFB:
F-VASI:
F-VASI75:
IFN:
IL:
JAK:
NSV:
PGIC-V:
SAE:
TEAE:
TEC:
T-VASI:

adverse event
body surface area
change from baseline
Facial Vitiligo Area Scoring Index
75% improvement on the Facial Vitiligo
Scoring Index
interferon
interleukin
Janus kinase
nonsegmental vitiligo
Patient Global Impression of ChangeVitiligo
serious adverse event
treatment-emergent adverse event
tyrosine kinase expressed in hepatocelluar carcinoma
Total Vitiligo Area Scoring Index

compliance with the Declaration of Helsinki and all
International Conference on Harmonization Good
Clinical Practice guidelines. All patients provided
written informed consent.
Patients
Eligible patients were aged 18-65 years with a
clinical diagnosis of NSV for $3 months, body
surface area (BSA) involvement of 4%-50% excluding
palms, soles, and feet, BSA facial involvement
$0.25%, excluding vermillions, and $1 active lesion,
defined as new/extending lesion(s) in the past
3 months confirmed by photographs/medical record, confetti-like lesion(s), trichrome lesion(s), or
Koebner phenomenon/phenomena excluding
history-based isomorphic reaction.
Patients were excluded if they had other types of
vitiligo, including segmental vitiligo (mixed vitiligo
permitted), or other disorders causing hypopigmentation. Additional exclusion criteria are described in
Supplementary Methods, available via Mendeley at
https://doi.org/10.17632/ctb8brksnm.1.
Randomization and treatment
In the dose-ranging period, patients were randomized (Supplementary Methods, available via
Mendeley at https://doi.org/10.17632/ctb8brksnm.
1) to 1 of 5 treatment groups or placebo as follows:
2 groups received a ritlecitinib loading dose of 100 or
200 mg daily for 4 weeks followed by maintenance
dosing of 50 mg daily for 20 weeks (200/50 and 100/
50 mg, respectively); 3 groups without a ritlecitinib
loading dose received 50, 30, or 10 mg daily for
24 weeks; or matching placebo for 24 weeks.
Patients were allocated to treatment in the extension period based on response at week 16 of the
dose-ranging period. Nonresponders (\50% change
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from baseline [%CFB] in Total-Vitiligo Area Scoring
Index [T-VASI]) were allocated to an open-label
brepocitinib group, an open-label ritlecitinib plus
narrow-band ultraviolet B therapy group, or a
blinded 200/50-mg ritlecitinib group. The blinded
200/50-mg ritlecitinib group is included in this
analysis.
Outcomes
The centrally-read Facial Vitiligo Area Scoring Index
(F-VASI) was assessed by 2 independent observers
based on facial photographs taken at the study site
(Supplementary Methods, available via Mendeley at
https://doi.org/10.1016/j.jaad.2021.05.050). The primary endpoint was the %CFB in the centrally-read
F-VASI at week 24; the key secondary endpoint was
the proportion of patients with $75% improvement on
the centrally-read F-VASI (F-VASI75) at week 24. The %
CFB in the centrally-read F-VASI at designated time
points were secondary endpoints in the dose-ranging
period (except week 24) and exploratory endpoints in
the extension period.
The locally-read F-VASI and T-VASI were assessed
by investigators at the site without the use of
photographs (Supplementary Methods). The %CFB
in locally-read F-VASI and T-VASI at designated time
points were secondary endpoints in the doseranging period and exploratory endpoints in the
extension period.
The Patient Global Impression of Change-Vitiligo
(PGIC-V) is a 1-item questionnaire to assess a
patient’s impression of disease improvement relative
to baseline on a 7-point Likert scale from ‘‘very much
improved’’ to ‘‘very much worse’’. The proportion of
patients achieving ‘‘very much improved’’ or ‘‘much
improved’’ on the PGIC-V was an exploratory
endpoint in the dose-ranging and extension periods.
Patients were monitored for adverse events (AEs)
from the time of informed consent through a
minimum 28 days after last study drug administration. The incidence of treatment-emergent AEs
(TEAEs), serious AEs (SAEs), and specific clinical
laboratory abnormalities were primary safety endpoints in the dose-ranging and extension periods.
Statistical analysis
The primary patient population for the efficacy
endpoints during the dose-ranging period was the
full analysis set, defined as all patients who received
$1 dose of randomized study medication and had a
baseline and $1 post-baseline measurement.
The safety analysis set included all patients who
received $1 dose of study medication. The primary
population for the extension period efficacy endpoints included all patients assigned to ritlecitinib
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200/50 mg in the extension period. The total sample
size for the study was computed to be ;330 randomized with the expectation of ;260 completers,
assuming 20% loss to follow-up within 6 months of
study initiation.
The %CFB in the centrally- and locally-read
F-VASI and locally-read T-VASI were analyzed using
ANCOVA (analysis of covariance) models, with
treatment, baseline score for the respective measure,
and Fitzpatrick skin type as covariates. Missing data
were handled using the observed case method. For
binary data, 90% confidence intervals (CIs) were
calculated using the Blyth-Still-Castella exact method
for 1-sample proportions, and 90% CIs and P values
of difference from placebo were calculated using the
Chan and Zhang exact method. Missing data were
handled using non-responder imputation or the
observed case method.
Adjustment for multiple comparisons was made
for the primary efficacy endpoint for the ritlecitinib
200/50-, 100/50-, and 50-mg groups with Hochberg’s
step-up procedure using observed P values. The
familywise Type I error rate was controlled at 1-sided
a = 0.05. No adjustments for multiple comparisons
were made for other analyses. Two-sided P values
are reported.

RESULTS
Patients
Dose-ranging period. Of 578 patients screened,
366 were randomized and 364 received treatment
(Supplementary Fig 1, available via Mendeley at
https://doi.org/10.1016/j.jaad.2021.05.050). Sixtysix patients (18.1%) discontinued treatment, most
commonly due to patient withdrawal (n = 29 [8.0%]).
Demographic and baseline characteristics were
generally similar across groups (Table I).
Extension period. One hundred eighty-seven
patients were assigned to ritlecitinib 200/50 mg in the
extension period (Supplementary Table I, available
via Mendeley at https://doi.org/10.1016/j.jaad.2021.
05.050). Twenty-nine patients (15.5%) discontinued
treatment, most commonly due to patient withdrawal (n = 12 [6.4%]).
Efficacy
Dose-ranging period. The mean (90% CI) %
CFB in centrally-read F-VASI at week 24 (primary
endpoint) was 21.2 ( 28.0, 14.4), 21.2 ( 28.0,
14.3), 18.5 ( 25.8, 11.2), 14.6 ( 23.6, 5.6),
3.0 ( 10.7, 4.7), and 2.1 ( 4.6, 8.8) for the
ritlecitinib 200/50-, 100/50-, 50-, 30-, and 10-mg,
and placebo groups, respectively (primary endpoint;
Fig 1, A; Supplementary Table II, available via
Mendeley at https://doi.org/10.1016/j.jaad.2021.05.
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050). The difference versus placebo was significant
for ritlecitinib 50 mg with or without a loading dose
(200/50 mg, adjusted P \ .001; 100/50 mg, adjusted
P \ .001; 50 mg, adjusted P \ .001) and 30 mg
(unadjusted P = .01). The difference versus placebo
was evident as early as week 8 for ritlecitinib 50 mg
with or without a loading dose (Fig 1, A).
In the ritlecitinib 200/50-, 100/50-, 50-, 30-, and
10-mg, and placebo groups, respectively, 12.1%,
8.5%, 7.7%, 2.7%, 2.3%, and 0% of patients achieved
centrally-read F-VASI75 at week 24 (key secondary
endpoint; Fig 1, B; Supplementary Table II). The
difference from placebo was significant for ritlecitinib 50 mg with or without a loading dose (200/
50 mg, unadjusted P = .008; 100/50 mg, unadjusted
P = .03; 50 mg, unadjusted P = .04).
Mean (90% CI) %CFB in locally-read T-VASI at
week 24 was 14.7 ( 20.4, 8.9), 19.2 ( 24.6,
13.8), 14.7 ( 20.1, 9.0), 14.0 ( 20.9, 7.2),
12.1 ( 18.5, 5.7), and 11.0 ( 16.5, 5.4) for the
ritlecitinib 200/50-, 100/50-, 50-, 30-, and 10-mg, and
placebo groups, respectively. The difference versus
placebo trended towards significant for ritlecitinib
50 mg with a 100 mg 4-week loading dose (unadjusted P = .07, Supplementary Table II).
The proportion of patients (90% CI) who achieved
‘‘very much improved’’ or ‘‘much improved’’ on the
PGIC-V at week 24 was 18.0% (10.5, 28.3), 21.4%
(12.9, 31.6), 12.0% (5.4, 21.2), 21.2% (11.7, 36.1),
15.0% (6.7, 26.9), and 8.9% (4.4, 17.3) in the
respective groups and was significantly greater
with ritlecitinib 100/50 mg versus placebo.
Extension period. Patients treated with ritlecitinib 200/50 mg in the extension period
demonstrated accelerated improvement on the
centrally-read F-VASI after week 28, regardless of
initial treatment allocation (Fig 1, C ). Mean (90% CI)
%CFB in centrally-read F-VASI at weeks 24 and 48,
respectively, was 19.0 ( 26.9, 11.0) and 63.4
( 72.5, 54.3) for the ritlecitinib 200/50 / 200/50mg group; 17.0 ( 25.4, 8.6) and 66.0 ( 76.8,
55.3) for the ritlecitinib 100/50 / 200/50-mg
group; 12.8 ( 21.5, 4.1) and 60.2 ( 69.9,
50.4) for the ritlecitinib 50 / 200/50-mg group;
11.5 ( 21.4, 1.6) and 66.1 ( 79.3, 52.9) for
the ritlecitinib 30 / 200/50-mg group; 1.2 ( 9.3,
6.8) and 42.1 ( 51.6, 32.7) for the ritlecitinib 10
/ 200/50-mg group; and 1.9 ( 5.9, 9.6) and 51.1
( 60.4, 41.9) for the placebo / ritlecitinib 200/50mg group. Continuous repigmentation with no
plateau was observed up to week 48
(Supplementary Fig 2, available via Mendeley at
https://doi.org/10.1016/j.jaad.2021.05.050).
The
mean %CFB in the locally-read F-VASI, excluding
patients with \0.5% baseline centrally-read BSA
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Table I. Demographic and baseline characteristics of patients in the dose-ranging period

Female, No. (%)
Age, mean (SD), y
Race, No. (%)
White
Black/African
American
Asian
American Indian or
Alaska Native
Multiracial
Not reported
Disease duration,
mean (SD), y
Received prior
medication, No. (%)
Full analysis set, No.
Total VASI score,
mean (SD), %
Locally read F-VASI,
mean (SD), %
Centrally read F-VASI,
mean (SD), %
Total BSA, mean
(SD), %
Fitzpatrick skin type,
No. (%)
I-II
III-VI

Ritlecitinib 200/
50 mg (N = 65)

Ritlecitinib 100/
50 mg (N = 67)

Ritlecitinib
Ritlecitinib
Ritlecitinib
50 mg (N = 67) 30 mg (N = 50) 10 mg (N = 49)

Placebo
(N = 66)

Total
(N = 364)

30 (46.2)
45.4 (12.2)

31 (46.3)
44.2 (11.2)

39 (58.2)
43.3 (10.4)

28 (56.0)
44.7 (13.5)

25 (51.0)
46.6 (10.0)

40 (60.6) 193 (53.0)
46.1 (11.5) 45.0 (11.5)

44 (67.7)
3 (4.6)

47 (70.1)
0

45 (67.2)
0

39 (78.0)
4 (8.0)

33 (67.3)
1 (2.0)

38 (57.6) 246 (67.6)
2 (3.0)
10 (2.7)

15 (23.1)
0

17 (25.4)
0

17 (25.4)
0

5 (10.0)
1 (2.0)

11 (22.4)
0

21 (31.8)
0

0
3 (4.6)
19.0 (12.4)

1 (1.5)
2 (3.0)
17.3 (12.8)

1 (1.5)
4 (6.0)
19.8 (12.8)

0
1 (2.0)
18.3 (13.3)

2 (4.1)
2 (4.1)
17.6 (12.5)

1 (1.5)
5 (1.4)
4 (6.1)
16 (4.4)
18.0 (13.1) 18.4 (12.8)

40 (61.5)

44 (65.7)

48 (71.6)

38 (76.0)

30 (61.2)

46 (69.7) 246 (67.6)

64
17.0 (10.2)

67
16.9 (11.4)

67
16.7 (10.5)

50
19.8 (12.0)

49
15.7 (10.1)

66
363
17.7 (10.6) 17.3 (10.8)

1.1 (1.0)

1.2 (1.0)

0.9 (0.7)

1.1 (0.8)

1.1 (1.0)

1.0 (0.8)

1.0 (0.9)

0.8 (0.9)

0.9 (0.8)

0.7 (0.6)

0.8 (0.8)

0.8 (0.8)

0.7 (0.7)

0.8 (0.8)

21.4 (12.3)

19.6 (12.7)

20.9 (11.7)

23.5 (12.8)

18.6 (10.8)

21.5 (12.7) 20.9 (12.2)

16 (25.0)
48 (75.0)

15 (22.4)
52 (77.6)

20 (29.9)
47 (70.1)

12 (24.0)
38 (76.0)

11 (22.4)
38 (77.6)

17 (25.8) 91 (25.1)
49 (74.2) 272 (74.9)

86 (23.6)
1 (0.3)

Daily dosing.
BSA, Body surface area; F-VASI, Facial Vitiligo Area Scoring Index; VASI, Vitiligo Area Scoring Index.

(post hoc analysis; Supplementary Fig 3, available
via Mendeley at https://doi.org/10.1016/j.jaad.2021.
05.050), and locally-read T-VASI (Supplementary Fig
4, available via Mendeley at https://doi.org/10.1016/
j.jaad.2021.05.050) showed similar trends of accelerated improvement in the extension period when all
patients received ritlecitinib 200/50 mg.
The proportion of patients (90% CI) who were
‘‘very much improved’’ or ‘‘much improved’’ on the
PGIC-V increased from week 24 to week 48 in all
treatment sequences, ranging from 2.9% (0.3, 11.9)
to 19.4% (8.8, 32.7) at week 24 and 10.7% (4.0, 23.8)
to 57.9% (38.6, 76.2) at week 48 (Supplementary Fig
5, available via Mendeley at https://doi.org/10.1016/
j.jaad.2021.05.050).
Safety
Dose-ranging period. There were 277 (76.1%)
patients with 756 TEAEs in the dose-ranging period
(Table II); most were mild (40.1%) or moderate

(33.0%) in severity. The 3 most common TEAEs
were nasopharyngitis (15.9%), upper respiratory
tract infection (11.5%), and headache (8.8%)
(Supplementary Table III, available via Mendeley at
https://doi.org/10.1016/j.jaad.2021.05.050). Similar
rates of infections and infestations were observed
across all groups. Nineteen (5.2%) patients discontinued treatment due to AEs during the
dose-ranging period. There were no dosedependent trends in TEAEs, SAEs, severe AEs, AEs
leading to discontinuation, herpes zoster AEs, or
most common AEs up to week 24. There were no
deaths in the study. No clinically meaningful trends
for hematology or chemistry laboratory parameters
were observed. Four (1.1%) patients had SAEs, all
considered unrelated to treatment by investigators
(Supplementary-Additional Safety Information,
available via Mendeley at https://doi.org/10.1016/j.
jaad.2021.05.050). Four patients had confirmed cases
of herpes zoster (all non-serious), 2 patients had
malignancies (nonmelanoma skin cancers), and
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Fig 1. Centrally read F-VASI for patients with vitiligo. (A) Percent change from baseline (CFB)
up to week 24 in the dose-ranging period, (B) proportion of patients achieving centrally read
75% improvement on the Facial Vitiligo Scoring Index at week 24 in the dose-ranging period,
and (C) percent CFB up to week 48 in patients treated with ritlecitinib 200/50 mg daily in the
extension period. Daily dosing. %CFB, Percent change from baseline; CI, confidence interval;
F-VASI, Facial Vitiligo Area Scoring Index; LS, least square.

there
were
no
thromboembolic
events
(Supplementary-Additional Safety Information).
Extension period. One hundred sixty-two of
187 patients (86.6%) had 647 TEAEs across the doseranging and extension periods (Supplementary
Table IV, available via Mendeley at https://doi.org/
10.1016/j.jaad.2021.05.050). The most common
TEAEs during the 48-week study period were
nasopharyngitis (20.3%), upper respiratory tract
infection (17.1%), and headache (13.4%)
(Supplementary Table V, available via Mendeley at

https://doi.org/10.1016/j.jaad.2021.05.050). No clinically meaningful trends for hematologic or chemistry laboratory parameters were observed across the
48 weeks in patients receiving ritlecitinib 200/50 mg
in the extension period (Supplementary Figs 6-10,
available via Mendeley at https://doi.org/10.1016/j.
jaad.2021.05.050).

DISCUSSION
This is a randomized, placebo-controlled study
of an oral, targeted immunomodulatory agent for
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Table II. Summary of treatment-emergent adverse events during the dose-ranging period

AEs, No.
Patients with AEs,
No. (%)
Patients with SAEs,
No. (%)
Patients with severe
AEs, No. (%)
Patients who
discontinued
study due to AEs,
No. (%)

Ritlecitinib 200/
50 mg (N = 65)

Ritlecitinib 100/
50 mg (N = 67)

Ritlecitinib
50 mg (N = 67)

Ritlecitinib
30 mg (N = 50)

Ritlecitinib
10 mg (N = 49)

Placebo
(N = 66)

Total
(N = 364)

166
56 (86.2)

131
45 (67.2)

132
54 (80.6)

88
30 (60.0)

95
40 (81.6)

0

0

1 (1.5)

1 (2.0)

1 (2.0)

1 (1.5)

4 (1.1)

2 (3.1)

0

5 (7.5)

1 (2.0)

1 (2.0)

2 (3.0)

11 (3.0)

2 (3.1)

4 (6.0)

5 (7.5)

2 (4.0)

3 (6.1)

3 (4.5)

19 (5.2)

144
756
52 (78.8) 277 (76.1)

Daily dosing.
AE, Adverse event; SAE, serious adverse event.

active NSV. Ritlecitinib 50 mg (with or without
loading dose)/30 mg showed significantly greater
%CFB in the centrally-read F-VASI than placebo at
week 24 (primary endpoint). The proportion of
patients who achieved centrally-read F-VASI75 at
week 24 was also significantly greater with ritlecitinib 50 mg (with or without loading dose) than
placebo (key secondary endpoint). Accelerated
improvement was observed after week 28 during
the extension period across Fitzpatrick skin types
(data not shown), and ritlecitinib up to 48 weeks
was well tolerated.
This study employed a patient-centric approach29
by examining patient-reported changes. During the
extension period, 7.7%-19.4% of patients achieved
clinically meaningful changes of ‘‘much improved’’
or ‘‘very much improved’’ in the ritlecitinib arms at
week 24, and this proportion more than doubled at
week 48 for most groups (24.0%-57.9%), suggesting
continuous patient-reported improvement with
longer treatment duration. This finding was directionally aligned with the F-VASI and T-VASI results at
weeks 24 and 48. Future clinical studies may
investigate additional vitiligo-specific health-related
quality of life outcomes that are of priority to patients
with vitiligo, using vitiligo-specific measures and the
PGIC-V.
Based on in vitro studies and cellular assays,
ritlecitinib has no effect on JAK1/JAK2/TYK2, suggesting no direct inhibitory effect on IFN-g/type 1
IFN signaling.25 However, ritlecitinib may decrease
production of IFN-g by activated CD81 T cells and
natural killer cells via an indirect mechanism, related
to TEC kinase inhibition.25 Furthermore, ritlecitinib

inhibits g-chain cytokines that may suppress pathogenic tissue-resident memory T cells.14,30-32 This
framework may explain the modest efficacy
observed at a relatively early time point (week 24)
that increases considerably at a later time point
(week 48).
Ritlecitinib is the first oral JAK3/TEC inhibitor
evaluated for vitiligo in a randomized phase 2 clinical
trial; however, previous case reports and series have
suggested efficacy of oral and topical JAK inhibitors
for vitiligo treatment. Reports of oral tofacitinib
(JAK1/JAK3 [ JAK2 inhibitor) in 1,33 2,34 and 1035
patients showed efficacy with vitiligo, respectively.
An additional case report on 1 patient with vitiligo
reported skin repigmentation after treatment with
oral ruxolitinib (JAK1/JAK2 inhibitor).36 Treatment
with ruxolitinib cream showed efficacy in a phase 2
study.37
As a systemic therapy, ritlecitinib may have
advantages over topical treatments and phototherapy in inducing repigmentation and preventing
disease spread. The former is especially important
for areas that may be more difficult to repigment.38
Treatment of large vitiligo lesions would also be an
advantage of oral agents like ritlecitinib.
Combination treatment with JAK inhibitors and
phototherapy could be considered,34 and future
studies will analyze combination therapy efficacy.
Limitations of this study included the exclusion of
patients with stable vitiligo only, although data
suggest ritlecitinib promotes repigmentation in stable lesions.39 The majority of patients were White,
with less than 5% of patients reporting as Black or
African-American. Higher baseline pigmentation
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could impact self-reported assessments and physician scoring. This is important to consider for future
studies, as patients with darker baseline skin tones
may have a more pronounced psychosocial burden
and can face greater social stigma.40,41 The COVID19 pandemic meant some virtual consultations,
which may have impacted the data. Low baseline
facial involvement in some patients may have made
assessment more challenging.
In conclusion, this phase 2 trial suggests that
ritlecitinib is an effective and well-tolerated treatment
for patients with active NSV. As indicated by the data
during the extension period, longer treatment duration may be required for optimal repigmentation.
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